New unfair contract term laws in Australia introduce large financial penalties
Significant changes to the unfair contract term provisions in the Australian Consumer Law, including potential financial penalties, will soon apply.
Griffith Hack announces the promotion of five team members
Griffith Hack is proud to announce the promotion of five members of our team, including the elevation of Jennifer Wyndham-Wheeler to principal.
Spotlight Series: Regenerative Medicine – Part 2
Welcome to the second article of our Spotlight Series on one of the most exciting frontiers of scientific research and innovation, regenerative medicine.
Griffith Hack celebrates World IP Day 2022
World Intellectual Property Day is being celebrated across the globe today, with this year’s theme shining a spotlight on IP and youth and how we can innovate for a better future.
Virus filtration patent gets clean bill of health
In a recent decision of the Australian Patent Office, a patent application directed to a membrane for filtering biological products was upheld following opposition.
Why are embryonic stem cells not able to be patented in Australia?
Despite not being specifically excluded under s18 of the Australian Patents Act, technology utilising embryonic stem cells is not able to be patented in Australia. Why is this so?
Spotlight Series: Regenerative Medicine – Part 1
The first in a five-part series on one of the most exciting frontiers of scientific research and innovation, regenerative medicine.
Unproven hypotheses in clinical trials can be novelty-destroying
We review the decision in Mylan Health Pty Ltd v Sun Pharma ANZ Pty Ltd which may have far-reaching implications for pharmaceutical patent holders or applicants in Australia.
CRISPR-Cas9 Update: Collision of Trends in IP and Life Sciences
CRISPR-Cas9 genome editing may not just be the greatest scientific breakthrough of this century, but also provides many lessons on patenting life science technologies.